Home › Funds › Rosalind Advisors, Inc. › AQST

Rosalind Advisors, Inc. position in AQST

AQUESTIVE THERAPEUTICS INC · Health Care

Rosalind Advisors, Inc. reported holding 2,000,000 shares of AQST (AQUESTIVE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$9.3M, representing 3.78% of its reported portfolio and ranking #9 among its reported holdings. Rosalind Advisors, Inc. has disclosed AQST holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

Latest position (Q3 2026)2.00M sh
Reported value held$9.26M
Portfolio Weight3.78%
First reportedQ1 2026
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Rosalind Advisors, Inc.'s AQST position evolved

Rosalind Advisors, Inc. first disclosed a stake in AQST in Q1 2026 at 250,000 shares (US$1.0M). The position peaked in Q3 2026 at 2,000,000 shares, worth US$9.3M. Across 3 filings, Rosalind Advisors, Inc. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 2,000,000 shares valued at US$9.3M — an increase of 1,750,000 shares quarter over quarter.. Notable position changes include a 700% increase in Q3 2026 (shares fell 16% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2026 250.00K $1.04M New
Q2 2026 250.00K $1.04M Hold
Q3 2026 2.00M $9.26M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AQST and 13F data

AQST (AQUESTIVE THERAPEUTICS INC) is a Health Care company. 38 other funds we track also report a position in AQST — the largest reported positions include Bratton Capital Management, L.P. (US$45.4M), Samsara BioCapital, LLC (US$10.4M), Propel Bio Management, LLC (US$8.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AQST

All AQST fund holders →

FAQ

How long has Rosalind Advisors, Inc. held AQST?

Rosalind Advisors, Inc. has disclosed AQST holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

What is Rosalind Advisors, Inc.'s current position in AQST?

As of Q3 2026, Rosalind Advisors, Inc. holds 2.00M shares of AQST (AQUESTIVE THERAPEUTICS INC), valued at $9.26M, representing 3.78% of its reported portfolio and ranking #9.

Has Rosalind Advisors, Inc. been buying or selling AQST?

In the latest 13F filing (Q3 2026), Rosalind Advisors, Inc. increased its position in AQST. The position peaked in Q3 2026 at 2.00M shares.

Which other funds hold AQST?

Other major institutional holders of AQST include Bratton Capital Management, L.P., Samsara BioCapital, LLC, Propel Bio Management, LLC, among 38 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.